This Magnificent S&P 500 Dividend Stock Is Down 18% -- Time to Buy?

Vertex Pharmaceuticals (NASDAQ: VRTX) is usually a market-beater, but it hasn't been so over the past year. The company's shares are down 18% over the trailing-12-month period due to a combination of headwinds.While that's not the best news for current shareholders, it may be great for those considering buying the stock. If the biotech can recover and get back to its market-beating ways, now might be a great time to initiate a position. Let's figure out whether Vertex still has what it takes.Vertex Pharmaceuticals faced several clinical setbacks over the past year. First, its drug suzetrigine (now marketed under the brand Journavx) disappointed in a phase 2 clinical trial for painful lumbosacral radiculopathy. While Vertex initially said it would explore ways to advance the medicine to phase 3 studies in this indication anyway, it eventually abandoned that project.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool